Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity

Inhalational anthrax has high mortality even with antibiotic treatment, and antitoxins are now recommended as an adjunct to standard antimicrobial regimens. The efficacy of obiltoxaximab, a monoclonal antibody against anthrax protective antigen (PA), was examined in multiple studies conducted in two...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Brent J., Shadiack, Annette M., Carpenter, Sarah, Sanford, Daniel, Henning, Lisa N., O'Connor, Edward, Gonzales, Nestor, Mondick, John, French, Jonathan, Stark, Gregory V., Fisher, Alan C., Casey, Leslie S., Serbina, Natalya V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2016
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038317/
https://www.ncbi.nlm.nih.gov/pubmed/27431222
http://dx.doi.org/10.1128/AAC.00972-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038317/
https://www.ncbi.nlm.nih.gov/pubmed/27431222
http://dx.doi.org/10.1128/AAC.00972-16

Ejemplares similares